RINGPU(SZ:300119) Zheng Quan Shi Bao·2025-12-18 18:08Core Viewpoint - RuiPu Bio, the first A-share listed company focused on veterinary medicine, aims for significant growth during the "14th Five-Year Plan" period, leveraging capital market operations and strategic investments in biomanufacturing [1][2] Financial Performance - In 2024, the company expects revenue to exceed 3 billion yuan, with a 14% year-on-year growth in the first three quarters of 2025, achieving 2.5 billion yuan in revenue and a net profit of 360 million yuan, marking a 46% increase [1] - The pet supply chain revenue reached 633 million yuan in 2024, reflecting a 37.66% year-on-year growth [1] Industry Positioning - RuiPu Bio holds the largest market share in the domestic veterinary medicine sector and has established a comprehensive industry chain covering 12 large-scale production bases across 8 provinces [1] - The company exports products to over 50 countries and regions worldwide [1] Research and Development - The company invests over 200 million yuan annually in R&D, accounting for 7.76% of its revenue, and has established 6 national-level innovation platforms [2] - RuiPu Bio has received 121 new veterinary drug registration certificates and holds 330 authorized patents [2] - In 2025, the company is set to receive clinical approval for the world's first mRNA vaccine for food animals, targeting porcine epidemic diarrhea virus [2] Strategic Goals - The company aims to become the leading player in China's animal health industry and rank among the top five globally, focusing on synthetic biology, mRNA vaccines, and genetic engineering [2] - RuiPu Bio plans to expand its global footprint, particularly in the "Belt and Road" markets, and to innovate within the "vaccine-drug-healthcare-medical service" ecosystem [2]